Pseudohypoparathyroidism type II and anticonvulsant rickets

Area of Science:

• Endocrinology
• Nephrology
• Pharmacology

Background:

• Pseudohypoparathyroidism (PHP) is a group of disorders characterized by resistance to parathyroid hormone (PTH).
• PHP type II is distinguished by normal urinary cyclic AMP excretion but impaired phosphaturic response to PTH.
• Anticonvulsant medications can affect mineral metabolism, potentially complicating diagnosis.

Observation:

• A patient on anticonvulsants presented with hypocalcemia, hyperphosphatemia, elevated PTH, and reduced 25-hydroxyvitamin D3.
• The patient exhibited a blunted phosphaturic response to exogenous PTH but a normal urinary cyclic AMP response.
• These clinical and laboratory findings were consistent with pseudohypoparathyroidism type II.

Findings:

• Oral Vitamin D3 administration corrected serum 25-hydroxyvitamin D3, calcium, and phosphorus levels.
• Following Vitamin D3 treatment, the phosphaturic response to PTH normalized.
• The patient's presentation suggests pseudohypoparathyroidism type II, with anticonvulsant therapy acting as a complicating factor.

Implications:

• This case highlights the importance of considering medication side effects in the diagnosis of mineral and bone disorders.
• Early diagnosis and management of pseudohypoparathyroidism type II are crucial for preventing long-term complications.
• Further research may elucidate the specific mechanisms by which anticonvulsants interact with PTH signaling pathways.